ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
"Exosomal therapy: a promising approach to alleviate renal dysfunction induced by hypoxia in neonatal seizures".
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Emerging regenerative strategies for spinal cord injury: exosome-derived mechanisms and therapeutic insights.Frontiers in neuroscience · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney damage represents a significant global health concern, influenced by various factors including oxygen imbalance. Mesenchymal stem cell exosomes have shown promise in modulating inflammatory cytokines, which may help in preventing or alleviating damage associated with inflammatory processes. A total of 50 Wistar rats were divided into control, exposure to a hypoxia, hypoxia plus saline injection, hypoxia plus exosome, and sham + exosome groups. At the end of experiment, kidney function biomarkers, antioxidant enzyme levels, malondialdehyde (MDA) levels, and concentrations of anti-inflammatory and pro-inflammatory cytokines, as well as gene expression, were assessed across all groups. The findings of this study indicated that hypoxia-induced nephropathy (HINS) leads to kidney damage, evidenced by a reduction in kidney biomarkers, an elevation in MDA levels, and a decrease in total antioxidant capacity (TAC), superoxide dismutase (SOD), and catalase (CAT) concentrations when compared to the control group. Additionally, inflammation markers were found to be elevated in HINS rats relative to the control group. In the groups treated with exosomes, there was a significant reduction in MDA levels and a notable increase in antioxidant levels compared to the untreated HINS group. Pro-inflammatory cytokine levels were markedly elevated in HINS rats, whereas exosome treatment resulted in a significant decrease in pro-inflammatory cytokines and an increase in anti-inflammatory cytokines when compared to the HINS group. The results of this study provide evidence that oxidative stress induced by hypoxia contributes to chronic kidney disorders. Furthermore, the findings suggest that exosome therapy may serve as a viable future treatment approach for enhancing kidney function.
Indexed as
Identifiers
40366397What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.